Delivery Order SPE2DB22D1202-SPE2DB25FVEZ7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,655.80 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector units on July 28, 2025, with completion expected by July 29, 2025. This delivery order represents a firm fixed-price purchase with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $1,464.31 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector supplies. This competitively awarded, firm fixed-price contract was issued on June 4, 2025, with an ultimate completion date of June 5, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. No set-aside designation was applied to this award, indicating open competition among qualified...
- The Defense Logistics Agency has awarded a delivery order valued at $1,067.72 to AmerisourceBergen Drug Corp for XYOSTED 100 MG/0.5 ML auto-injector pharmaceutical supplies. The contract is a firm fixed price delivery order with an ultimate completion date of June 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability...
- The Defense Logistics Agency awarded a delivery order valued at $1,150.15 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 mL auto-injector supplies. The contract, which is non-set-aside and competitively awarded, was issued on August 1, 2025, with an ultimate completion date of August 4, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order operates under...
- The Defense Logistics Agency (DLA) awarded a $1,629.66 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 mL auto-injector supplies on May 8, 2025, with completion scheduled for May 9, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen's Corporate Office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,731.01. This firm fixed-price delivery order, which is due for completion by August 7, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award carries no set-aside designation, indicating it was competitively awarded. The pharmaceutical...
- The Defense Logistics Agency awarded a $1,494.88 delivery order to AmerisourceBergen Drug Corp for XYOSTED 50 mg/0.5 mL auto-injector supplies, with an ultimate completion date of June 20, 2025. This non-set-aside, firm fixed price delivery order was issued on June 18, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a $2,665.27 delivery order to AmerisourceBergen Drug Corp for XYOSTED 100 mg/0.5 ml auto-injector supplies on September 16, 2025, with completion targeted for September 17, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded order fulfilled from AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units, valued at $1,384.82 under a firm fixed price contract structure. This delivery order represents a competitive award with no set-aside designation and is scheduled for completion by September 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVEZ7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,524.90 to AmerisourceBergen Drug Corp for XYOSTED 75 mg/0.5 ml auto-injector supplies on July 18, 2025, with completion targeted for July 21, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award based on capability. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical delivery order. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vehicle running through December 2026 that provides comprehensive pharmaceutical and medical supply support to military healthcare programs globally. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical devices across multiple therapeutic domains. The company's contract awards with DLA demonstrate consistent capability to meet federal procurement requirements through open competition, supporting critical medical supply chains for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 7/18/25 |